Physician profile
Angela K Golden
NPI 1952310823
$378,406.45
in general payments reported to CMS, 2019-2025
8 companies · $98K in 2025
The $98K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,771 · 2021: $28K · 2022: $64K · 2023: $65K · 2024: $122K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Consulting Fee: $50K · Travel and Lodging: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Food and Beverage: $4,804 · Honoraria: $3,020 · Education: $72.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,440.93 |
| Consulting Fee | $49,565.00 |
| Travel and Lodging | $33,128.28 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,495.20 |
| Food and Beverage | $4,804.31 |
| Honoraria | $3,020.00 |
| Education | $72.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152,251.15 | 2020-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $132,322.28 | 2022-2025 | Zepbound, Mounjaro |
| Acella Pharmaceuticals, LLC | $29,748.25 | 2021-2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $28,678.11 | 2021-2025 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,040.65 | 2023-2025 | |
| Eli Lilly and Company | $11,863.43 | 2022-2023 | Mounjaro |
| Shield Therapeutics INC | $480.00 | 2022 | |
| Exact Sciences Corporation | $22.58 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.